At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Pazopanib 800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Breast Cancer and Breast Neoplasm. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive advanced breast cancer progressing on the same NSAI hormone therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Breast Neoplasm
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartApr 2012
Primary CompletionDec 2015
Study CompletionOct 2019
TodayJul 2026
First PostedNov 8, 2011
Enrollment StartApr 27, 2012
Primary CompletionDec 7, 2015
Study CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.7 years ago
Interventions
Pazopanibdrug
Oral, 800mg tablet daily per cycle